Trials / Completed
CompletedNCT00532428
Long Term Effects of Raloxifene Treatment on Bone Quality
Long-Term Effects of Raloxifene Treatment on Bone Quality: A Cross-Sectional Study of Postmenopausal Women With Osteoporosis Previously Enrolled in the Continuing Outcomes Relevant to Evista Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the Continuing Outcomes Relevant to Evista Study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raloxifene | 60 mg QD |
| DRUG | Raloxifene | 120 mg QD |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2003-04-01
- Completion
- 2003-09-01
- First posted
- 2007-09-20
- Last updated
- 2007-09-20
Locations
7 sites across 4 countries: United States, Mexico, Netherlands, Spain
Source: ClinicalTrials.gov record NCT00532428. Inclusion in this directory is not an endorsement.